Cagrilintide Alone Was Never the Endgame.
Cagrilintide's own trial program shows why it isn't marketed alone: in the same head-to-head Phase 3 trial, 2.4 mg of cagrilintide by itself produced less weight loss than semaglutide by itself. Novo Nordisk's real bet, and the one it has actually filed with the FDA, is the combination drug CagriSema, not a standalone cagrilintide product.
Reviewed by the PepGuard team · Last reviewed Jul 28, 2026
Long-acting amylin analogue under clinical investigation for weight management · also called AM833, long-acting amylin analogue
Photo: Jorge Alberto Vega Barrera / UnsplashNovo Nordisk tested cagrilintide by itself. It lost to semaglutide by itself.
REDEFINE 1, a 3,417-person Phase 3 trial, wasn’t built to test cagrilintide on its own. It was built to test CagriSema, Novo Nordisk’s combination of cagrilintide (2.4 mg) with semaglutide (2.4 mg), and it used both individual drugs as comparator arms to prove the combination adds something. At 68 weeks: the CagriSema combination produced 22.7% weight loss. Semaglutide alone produced 16.1%. Cagrilintide alone, at the same 2.4 mg dose vendors cite, produced 11.8%, the weakest of the three active arms, in the very trial designed to showcase it.
That number is the honest answer to what cagrilintide, by itself, actually does in the best human data available. It isn’t a failure exactly, it’s real weight loss over placebo’s 2.3%, it’s just not the story anyone selling “cagrilintide” online is telling.
What the trials actually dosed.
| What's cited | Range |
|---|---|
| Phase 2 dose-finding arms | 0.3 to 4.5 mg, subcutaneous, once weekly |
| Phase 3 fixed comparator dose (REDEFINE 1/2) | 2.4 mg, subcutaneous, once weekly |
| Dose escalation in the Phase 2 study | Up to 6 weeks before the maintenance dose |
| Human dose for a purchased research vial | Not established |
The figures below are study arms, included to describe what researchers tested. They are not a dosing schedule for weight loss. Both the Phase 2 trial and the Phase 3 program used once-weekly cagrilintide with a dose-escalation period; neither tested vendor reconstitution instructions, syringe units, or unsupervised combinations.
Cagrilintide alone versus the combination product.
| Signal | Frequency | Context |
|---|---|---|
| Gastrointestinal adverse events (cagrilintide alone) | commonly reported | 41% to 63% across cagrilintide groups versus 32% with placebo in the 26-week Phase 2 trial; nausea was the most frequent event. |
| Gastrointestinal adverse events (CagriSema combination) | commonly reported | In the Phase 3 REDEFINE 1 trial, 79.6% of the CagriSema (cagrilintide + semaglutide) group reported a GI adverse event versus 39.9% with placebo, a higher rate than cagrilintide alone. This is the combination product's rate, not cagrilintide's alone, and should not be conflated with it. |
| Nausea, constipation, or diarrhoea | commonly reported | Reported in both the Phase 2 and Phase 3 programs and should not be reduced to a generic 'GLP-1 side effect' label because cagrilintide is an amylin analogue. |
| Long-term safety outside a trial | unknown / not studied | The longest cagrilintide-alone data is 68 weeks inside a controlled Phase 3 comparator arm, not long-term self-administration outside a trial. |
An FDA decision is coming. Not for cagrilintide alone.
In December 2025, Novo Nordisk filed a New Drug Application with the FDA for CagriSema, its fixed-dose cagrilintide-plus-semaglutide combination, and has said an FDA decision is anticipated by late 2026. That’s a real, dated, verifiable regulatory milestone. It is also not a filing for cagrilintide as a standalone product, and there’s no indication Novo Nordisk plans to pursue one. If CagriSema is approved, cagrilintide will reach the market bundled with semaglutide, at a dose the trials show underperforms that combination.
A vendor got caught selling cagrilintide with CagriSema’s numbers.
The FDA has stated directly that “retatrutide and cagrilintide cannot be used in compounding under federal law,” and are “not components of FDA-approved drugs.” A December 2025 warning letter to a compounding-ingredient distributor, Darmerica, LLC, names “cagrilintide acetate” specifically as an active ingredient “ineligible for use in human drug compounding under section 503A”, the identical legal reasoning used against retatrutide. Cagrilintide doesn’t appear on either the FDA’s 503A or 503B nominated-substance lists at all.
A separate March 2026 warning letter to a different seller, Prime Sciences, shows exactly what that looks like in practice: the FDA cited the company for advertising a “40.4% versus 16.2%” weight-loss comparison directly on its cagrilintide product page. Those numbers are real, they just describe CagriSema, the combination drug, not the cagrilintide-alone product being sold on that page, which performed at roughly 11.8% in the same trial. Real trial data, attached to the wrong product.
Cagrilintide and retatrutide are not substitutes
Cagrilintide is an amylin analogue. Retatrutide targets GIP, GLP-1, and glucagon receptors. Their trial designs, outcomes, and adverse-event profiles cannot be combined into one dosing chart.
Every claim above, traced back.
Two Phase 2/Phase 3 trial results, a peer-reviewed NEJM paper, Novo Nordisk’s own FDA filing announcement, and two FDA warning letters naming cagrilintide directly. Click through and check them yourself.
Cagrilintide questions, answered.
No, neither alone nor in combination. Novo Nordisk filed a New Drug Application for CagriSema, the cagrilintide-plus-semaglutide combination, in December 2025, and has said an FDA decision is anticipated by late 2026. There is no filing, and no indication of a planned filing, for cagrilintide as a standalone product.
The original 26-week Phase 2 trial tested 0.3 to 4.5 mg once weekly with dose escalation. A later Phase 3 trial (REDEFINE 1) used a fixed 2.4 mg once-weekly dose as one of its comparator arms. Both describe study designs, not a recommendation for using a research-vendor vial.
In the original 706-person Phase 2 trial, mean weight reduction ranged from 6.0% to 10.8% across cagrilintide doses at 26 weeks, versus 3.0% with placebo. In the larger Phase 3 REDEFINE 1 trial, the 2.4 mg cagrilintide-alone comparator arm produced 11.8% weight loss at 68 weeks, versus 16.1% for semaglutide alone and 22.7% for the CagriSema combination, in the same head-to-head trial. Cagrilintide by itself underperformed semaglutide by itself.
Cagrilintide is a single amylin analogue. CagriSema is Novo Nordisk's fixed-dose combination of that same cagrilintide with semaglutide (the active ingredient in Ozempic and Wegovy). CagriSema is the product with real Phase 3 results and an actual FDA submission. Cagrilintide alone is not being pursued as a standalone drug.
No legitimate channel sells it. The FDA has stated directly that cagrilintide "cannot be used in compounding under federal law," and a December 2025 warning letter to a compounding-ingredient supplier lists cagrilintide acetate by name as ineligible for compounding under section 503A, the same legal reasoning used against retatrutide.
Often because they're citing CagriSema's combination-drug trial results on a page selling cagrilintide alone. In one documented case, the FDA cited a vendor for advertising a 40.4%-versus-16.2% weight-loss comparison on its cagrilintide product page — numbers that came from the CagriSema combination trial, not from cagrilintide by itself, which performed closer to 11.8% in the same trial.
Keep researching.
This is a preview of the Cagrilintide report.
Create your account to check any peptide against the full research base.